84 completed, 2 active not recruiting, 2 unknown, 1 not yet recruiting. 90 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 90 | Completed 84, Active not recruiting 2, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Unknown 1 |
Follow Bordetella Infections: new trials by email Literature Review of Bordetella Infections trials Research Report on Bordetella Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BK1803 in Healthy Infants BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection - Pertussis, Diphtheria | Phase 3 | Not yet recruiting | Tanabe Pharma Corporation | 344 | 2026-10-01 | 2026-08-28 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp)), 23-valent Pneumococcal Polysaccharide Vaccine (PPV23), Tdcp - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | CanSino Biologics Inc. | 1820 | 2024-12-20 | 2026-08-26 |
| Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines Pertagen®, Revaxis® - Pertussis, Vaccine-Preventable Diseases | Phase 2 / Phase 3 | Unknown | University Hospital, Geneva | 100 | 2022-02-07 | 2022-01-18 |
| A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed, Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed, Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine - Whooping Cough, Diphtheria | Phase 3 | Active not recruiting | China National Biotec Group Company Limited | 2898 | 2021-10-22 | 2025-09-15 |
| To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years DTaP-IPV combination vaccine - Diphtheria, Tetanus | Phase 3 | Unknown | Boryung Biopharma Co., Ltd. | 249 | 2019-12-26 | 2020-11-06 |
| Confirmatory Study of BK1310 in Healthy Infants DPT-IPV-Hib, Hib vaccine, DPT-IPV - Tetanus, Diphtheria | Phase 3 | Completed | Tanabe Pharma Corporation | 267 | 2019-04-01 | 2026-01-06 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
| Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects Boostrix - Diphtheria-Tetanus-acellular Pertussis Vaccines | Phase 3 | Completed | GlaxoSmithKline | 448 | 2018-01-26 | 2020-10-27 |
| A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Infanrix-IPV/Hib - Diphtheria, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 235 | 2016-09-13 | 2019-09-24 |
| DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 53 | 2016-07-14 | 2022-04-05 |
| Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012) Blood Sample - Hepatitis B, Pertussis | Phase 3 | Completed | MCM Vaccines B.V. | 754 | 2016-04-26 | 2020-06-09 |
| Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth Hexaxim® - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 354 | 2015-04-20 | 2022-04-05 |
| Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS DTaP-IPV combination vaccine, DTaP vaccine and IPV vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Boryung Pharmaceutical Co., Ltd | 476 | 2015-02-02 | 2023-06-28 |
| DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants DTaP-IPV/Hib Combined vaccine, DTaP-IPV vaccine and Hib vaccine - Tetanus, Diphtheria | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 424 | 2014-10-01 | 2022-04-25 |
| Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301), Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid) - Diphtheria, Tetanus | Phase 3 | Completed | Tanabe Pharma Corporation | 446 | 2014-04-01 | 2026-01-06 |
| DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants DTaP-IPV-Hep B-PRP~T combined vaccine, DTaP-IPV//PRP~T and Hepatitis B vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 310 | 2014-03-01 | 2017-04-26 |
| Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, Diphtheria and Tetanus toxoids adsorbed - Tetanus, Diphtheria | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 534 | 2014-03-01 | 2017-05-30 |
| Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 177 | 2014-02-01 | 2015-10-20 |
| Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months Infants DTaP Vaccine A, DTaP Vaccine B - Pertussis | Phase 3 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 1200 | 2013-12-01 | 2015-06-23 |
Showing 20 of 90. Sign in to see all of them.
Whooping Cough (90) · Tetanus (78) · Diphtheria (77) · Poliomyelitis (48) · Haemophilus Infections (43) · Hepatitis B (43) · Bacterial Infections (7) · Virus Diseases (6) · Influenza, Human (4) · Meningococcal Infections (4) · Communicable Diseases (3) · Immune System Diseases (3) · Meningitis (3) · Rare Diseases (3) · Measles (2)
Bacterial Infections and Mycoses (90) · Gram-Negative Bacterial Infections (90) · Infections (90) · Respiratory Tract Diseases (90) · Respiratory Tract Infections (90) · Bacterial Infections (83) · Gram-Positive Bacterial Infections (82) · Clostridium Infections (78) · Actinomycetales Infections (77) · Corynebacterium Infections (77) · Virus Diseases (59) · Nervous System Diseases (52) · Neuroinflammatory Diseases (52) · RNA Virus Infections (51)
Tetanus Toxoid (17) · Diphtheria-Tetanus-acellular Pertussis Vaccines (12) · DTaP-IPV-HB-PRP-T vaccine (9) · Pentavac (8) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (8) · adacel (7) · Heptavalent Pneumococcal Conjugate Vaccine (6) · Hiberix (6) · pentacel (5) · 13-valent pneumococcal vaccine (4) · Boostrix (4) · Diphtheria-Tetanus Vaccine (4) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (4) · Poliovirus Vaccine, Inactivated (4) · Poliovirus Vaccine, Oral (4)
Sanofi Pasteur, a Sanofi Company (33) · GlaxoSmithKline (16) · Sanofi (10) · Merck Sharp & Dohme LLC (7) · MCM Vaccines B.V. (3) · Tanabe Pharma Corporation (3) · Crucell Holland BV (2) · LG Chem (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Novartis Vaccines (2) · Boryung Biopharma Co., Ltd. (1) · Boryung Pharmaceutical Co., Ltd (1) · CanSino Biologics Inc. (1) · Children's Hospital Medical Center, Cincinnati (1) · China National Biotec Group Company Limited (1)
United States (9) · Philippines (7) · South Korea (7) · China (6) · Germany (6) · India (5) · Japan (5) · Costa Rica (4) · South Africa (4) · Thailand (4) · Colombia (3) · France (3) · Mexico (3) · Russia (3) · Vietnam (3)
Anne Fiquet, MD (1) · Byeonguk Eun (1) · Dagmar Dilloo, MD, PhD (1) · Donato Greco (1) · Edison Alberto, MD (1) · HJ Jung (1) · Hanqing He (1) · Josefina Carlos, MD (1)
PMID 14670310, PMID 17090650, PMID 19095033, PMID 19117896, PMID 19952980, PMID 20189491, PMID 20439595, PMID 21219984, PMID 21289531, PMID 21334243, PMID 21807056, PMID 21817954, PMID 22001281, PMID 22157567, PMID 22273029, PMID 22349525, PMID 22475857, PMID 22531237, PMID 22691430, PMID 23783081, PMID 23966556, PMID 25765966, PMID 25879974, PMID 27288217, PMID 27510380, PMID 27846055, PMID 27846058, PMID 27879555, PMID 28522338, PMID 28984909, PMID 29100709, PMID 29443825, PMID 29452372, PMID 29789243, PMID 29960800, PMID 30010773, PMID 31056697, PMID 31307216, PMID 31689166, PMID 32048889, PMID 32307307, PMID 32379201, PMID 32526188, PMID 32943001, PMID 38461048, PMID 38582691, PMID 41276263
2015 (1), 2016 (1), 2018 (1)